Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Tislelizumab is now approved for seven indications in China
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
The interim data combines three mRNAs into one therapy injected directly into the tumour
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
Subscribe To Our Newsletter & Stay Updated
